Latest News
Celldex Therapeutics, Inc.
- Chronic Spontaneous Urticaria Clinical Trials Update 2026: Phase-Wise Pipeline Status, Drug Profiles, and Key Developers | Allakos, AstraZeneca, Biosana, Celldex Therapeutics, Celltrion, Eli Lilly
- HC Wainwright sets USD 64.00 target for Celldex Therapeutics stock
- Celldex Therapeutics (NasdaqCM:CLDX) Stock Forecast & Analyst Predictions
- Learn Why The Bull Case For Celldex Therapeutics Stock Could Change Following Shareholder Investigation
- Celldex Therapeutics stock fell 4.84 percent to USD 27.53 on October 16, 2026
- Law firm investigates Celldex Therapeutics for possible breach of fiduciary duties.
- Celldex Therapeutics: Trying To Put Its Troubled History Behind It (NASDAQ:CLDX)
- FMR LLC and Abigail P. Johnson Reveal 10.7% Stake in Celldex Therapeutics Inc.
- An investment firm reports a passive stake of 8.4 million shares in Celldex Therapeutics (CLDX).
- Is Celldex Therapeutics (CLDX) Fully Priced After Its Phase 3 Win?
Headlines from the last 30 days, linking to the original publishers. See all market news →